Lifecare AS (DE:LFC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Lifecare ASA has announced the successful completion of a 12-week trial for its advanced Continuous Glucose Monitor (CGM) on a veterinary patient, with no negative health effects observed. The trial, which is a part of the company’s efforts to validate the sensor’s durability and biocompatibility, showed the Sencell sensor’s potential to outperform current CGM systems in the market. Lifecare’s next steps involve enrolling more animal patients to further assess the sensor’s performance and glucose monitoring accuracy.
For further insights into DE:LFC stock, check out TipRanks’ Stock Analysis page.
